A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Defin ...
Parkinson Disease
Drug: Cohort 1:NilotinibOralCapsules (150mg or 300mg);Drug: Cohort 2: NilotinibOralCapsules (dose to be determined from Cohort 1);Drug: Placebo Drug: Cohort 1:NilotinibOralCapsules (150mg or 300mg);Drug: Cohort 2: NilotinibOralCapsules (dos ...
Northwestern University
University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotini ...
Parkinson Disease;Parkinsons Disease With Dementia